HOME >> MEDICINE >> NEWS
New radioimmunotherapy drug proves highly effective for killing off B cell non-Hodgkins lymphoma

ROCHESTER, MINN. -- A Mayo Clinic study indicates the first of a new class of drugs involving radioimmunotherapy benefited a significant number of patients with low-grade B cell non-Hodgkins lymphoma who have exhausted treatment options.

The study, published in the May 15, 2002, issue of Journal of Clinical Oncology, investigated the ability of the drug Zevalin to hone in on and kill off the non-Hodgkins lymphoma B cells. Zevalin is the first radioimmunotherapy drug developed specifically to fight this common but usually fatal cancer of the lymph glands that, for unknown reasons, is on the increase in the United States. About 56,000 people are diagnosed with this cancer annually.

The randomized study involved 143 patients with B cell non-Hodgkins lymphoma who had previously failed the standard chemotherapy treatments. The study found that 80 percent of patients who received Zevalin experienced a positive response in that their tumor shrunk. That compared to a 56 percent response rate in patients receiving only Rituxan, another drug used to treat the cancer.

Most noteworthy, 30 percent of the patients receiving Zevalin achieved complete remission with no evidence of the cancer present, compared to only 16 percent of patients taking Rituxan.

Radioimmunotherapy combines monoclonal antibodies, which are antibodies produced in a laboratory to react against a cancer cell, with the ability of radiation to kill off cancer cells. The mixture of radiation and antibodies is given intravenously and travels through the bloodstream to the cancer cells.

Unlike chemotherapy which goes through the whole body, Zevalin carries the radiation payload directly to the tumor, says Thomas Witzig, M.D., a Mayo Clinic hematologist. The drug radiates only about a five millimeter area around the tumor.

Along with its ability to hone in on cancer cells, the drug is easier on patients physically.

One treatment is required on an outpatient ba
'"/>

Contact: Mary Lawson
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
13-May-2002


Page: 1 2

Related medicine news :

1. New radioimmunotherapy cancer treatment
2. Hormonal treatment improves survival in high-risk prostate cancer patients
3. Growth hormone treatment improves symptoms of metabolic disorder in postmenopausal women
4. MRI proves useful in assessment of suspected breast cancer patients
5. New substance that improves the photodetection of bladder cancer gains market approval
6. Most advanced CT scanner improves imaging of heart, avoids need for surgical inspection
7. Columbia study finds hemophilia therapy dramatically improves outcomes for bleeding stroke
8. New test improves detection of bladder cancer
9. New mosquito control strategy proves successful against dengue fever
10. Study proves catheter ablation safe for patients
11. Adding radiation therapy to chemotherapy improves survival in patients with high-risk breast cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... , ... The American Board of Family Medicine's (ABFM) Board of Directors has ... succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve in the ... at the end of 2018. Upon assuming the role of President and CEO on ...
(Date:10/13/2017)... ... 13, 2017 , ... Apple Rehab Shelton Lakes , which specializes in ... the facility as part of a disaster drill on October 3rd. , Apple Rehab ... City Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... services for healthcare compliance program management, will showcase a range of technology and ... for Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical ... Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. ... honor of Morris F. Collen, a pioneer in the field of medical informatics, this ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
(Date:9/27/2017)... MIAMI , Sept. 27, 2017  Commended for their ... recent notable awards. Ranked as number one in the South ... ninth time in Inc. 5000 yearly list, the national specialty ... CEO, Armando Bardisa will soon be honored by ... Set to receive his award ...
(Date:9/25/2017)... AMSTERDAM , Sept. 25, 2017   ... Trial Master File solutions, today—from the IQPC Trial ... Amsterdam , NL)—announced that EastHORN Clinical Services ... its clinical programs and TMF management. EastHORN, a ... Montrium,s eTMF platform to increase transparency to enable ...
Breaking Medicine Technology:
Cached News: